Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Igc Pharma Inc's Business Segments
Igc Pharma Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q2 FY2026
Reportable Segments
-
Largest Segment
-
Total Revenue
$ 0
Regions Reported
-
Revenue by Product & Service Category - Q2 FY2026
- White Labeling Services96.6%
- Wellness and Lifestyle3.4%
Revenue by Product & Service Category - Q2 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| White Labeling Services | $ 0 | 96.6% |
| Wellness and Lifestyle | $ 0 | 3.4% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Igc Pharma Inc
Igc Pharma Inc, also known as India Globalization Capital Inc, is a biotechnology company that focuses on researching, developing, and commercializing cannabinoid-based therapies for various medical conditions. They are based in Maryland, United States. The company is listed on the NYSE American exchange under the ticker symbol IGC.
Igc Pharma specializes in the development of cannabinoid-based combination therapies that target diseases such as Alzheimer's, Parkinson's, epilepsy, and post-traumatic stress disorder (PTSD). They believe that cannabinoids, derived from the cannabis plant, have the potential to provide therapeutic benefits for these conditions.
The company's product pipeline includes several proprietary cannabinoid-based therapies. One of their leading candidates is IGC-AD1, which is being developed as a potential treatment for Alzheimer's disease. This therapy aims to target beta-amyloid plaque, a key pathological feature of Alzheimer's, and reduce its accumulation in the brain.
In addition to Alzheimer's disease, Igc Pharma is also researching the use of cannabinoids for other neurodegenerative conditions such as Parkinson's disease. They have a candidate called IGC-AP1 that is being evaluated as a potential treatment for this condition. The therapy aims to mitigate the motor symptoms associated with Parkinson's, such as tremors and rigidity.
The company's research efforts also extend to epilepsy, a neurological disorder characterized by recurrent seizures. IGC is developing a cannabinoid-based therapy called IGC-SE1, which aims to reduce the frequency and severity of seizures in patients with epilepsy.
Alongside their focus on neurodegenerative diseases and epilepsy, Igc Pharma is exploring the potential use of cannabinoids in treating PTSD. They are developing a therapy called IGC-AD2, which targets the symptoms of PTSD such as anxiety and flashbacks.
Aside from their therapeutic development efforts, Igc Pharma is also engaged in the creation of novel delivery platforms for medical cannabinoids. They have developed a patented delivery system known as the Hyalolex technology, which enhances the bioavailability and effectiveness of cannabinoid-based therapies.
In terms of regulatory approvals, Igc Pharma has received clearances from the United States Food and Drug Administration (FDA) for several of their investigational new drug applications. These approvals allow them to conduct clinical trials and advance their therapies towards commercialization.
Overall, Igc Pharma Inc is a biotechnology company that is dedicated to leveraging the potential of cannabinoids for the development of novel therapies targeting various medical conditions. Their extensive product pipeline and commitment to research and development position them as a significant player in the field of cannabinoid-based therapeutics.
Igc Pharma specializes in the development of cannabinoid-based combination therapies that target diseases such as Alzheimer's, Parkinson's, epilepsy, and post-traumatic stress disorder (PTSD). They believe that cannabinoids, derived from the cannabis plant, have the potential to provide therapeutic benefits for these conditions.
The company's product pipeline includes several proprietary cannabinoid-based therapies. One of their leading candidates is IGC-AD1, which is being developed as a potential treatment for Alzheimer's disease. This therapy aims to target beta-amyloid plaque, a key pathological feature of Alzheimer's, and reduce its accumulation in the brain.
In addition to Alzheimer's disease, Igc Pharma is also researching the use of cannabinoids for other neurodegenerative conditions such as Parkinson's disease. They have a candidate called IGC-AP1 that is being evaluated as a potential treatment for this condition. The therapy aims to mitigate the motor symptoms associated with Parkinson's, such as tremors and rigidity.
The company's research efforts also extend to epilepsy, a neurological disorder characterized by recurrent seizures. IGC is developing a cannabinoid-based therapy called IGC-SE1, which aims to reduce the frequency and severity of seizures in patients with epilepsy.
Alongside their focus on neurodegenerative diseases and epilepsy, Igc Pharma is exploring the potential use of cannabinoids in treating PTSD. They are developing a therapy called IGC-AD2, which targets the symptoms of PTSD such as anxiety and flashbacks.
Aside from their therapeutic development efforts, Igc Pharma is also engaged in the creation of novel delivery platforms for medical cannabinoids. They have developed a patented delivery system known as the Hyalolex technology, which enhances the bioavailability and effectiveness of cannabinoid-based therapies.
In terms of regulatory approvals, Igc Pharma has received clearances from the United States Food and Drug Administration (FDA) for several of their investigational new drug applications. These approvals allow them to conduct clinical trials and advance their therapies towards commercialization.
Overall, Igc Pharma Inc is a biotechnology company that is dedicated to leveraging the potential of cannabinoids for the development of novel therapies targeting various medical conditions. Their extensive product pipeline and commitment to research and development position them as a significant player in the field of cannabinoid-based therapeutics.
India Globalization Capital Inc. (IGC) operates primarily in the fields of healthcare, wellness, and technology, focusing on sectors that have significant growth potential. The company has diversified its offerings into various segments, products, and services, working towards serving both local and global markets.
Segments
1. Cannabis and Related Products:
- Medical Cannabis: IGC has been investing in the medical cannabis sector, focusing on developing formulations that can be used for treating various ailments. This includes research and development of cannabinoid-based products that cater to medical needs. The company aims to capitalize on the growing acceptance and legalization of cannabis across various regions.
2. Pharmaceuticals and Nutraceuticals:
- Nutraceutical Products: The company is involved in developing a range of nutraceuticals derived from natural sources, aimed at promoting health and wellness. These products often include dietary supplements and herbal formulations.
- Pharmaceutical Development: IGC is also exploring the pharmaceutical sector by developing drugs that address critical health issues, particularly those related to chronic diseases and conditions prevalent in the markets it targets.
3. Technology Solutions:
- Innovative Technologies: IGC is engaged in developing technology solutions that enhance operations in its core sectors. This could range from software development for healthcare management to digital platforms that facilitate patient interactions or telemedicine.
Products
1. Medicinal Products:
- Cannabidiol (CBD) Forms: The company offers various CBD products aimed at alleviating symptoms of chronic pain, anxiety, and other medical conditions. These products may come in capsules, oils, tinctures, and topical applications.
- Pharmaceutical Formulations: IGC is working on formulations that leverage pharmaceutical compounds combined with natural ingredients to treat illnesses more effectively.
2. Health Supplements:
- Vitamins and Minerals: The company markets a range of health supplements tailored for different demographics and health needs.
- Herbal Products: Formulations based on traditional medicinal practices are also part of the product line, focusing on holistic wellness.
3. Technology Products:
- Software Solutions: The development of software applications that support health care providers in managing patient care, enhancing communication, and streamlining service delivery is a key focus.
Services
1. Consultation Services:
- IGC provides consulting services in relation to product development, regulatory compliance, and market entry strategies in the healthcare sector.
2. Research and Development:
- The company offers R&D services, focusing on creating novel formulations, conducting clinical trials, and ensuring compliance with health regulations.
3. Distribution and Logistics:
- IGC manages logistics and distribution services to ensure that its products reach the market efficiently and effectively. This includes establishing supply chain networks that support the timely delivery of medical and wellness products.
4. Education and Training:
- IGC is likely involved in providing educational resources to healthcare providers, enabling them to understand and utilize its products effectively while also training personnel in the adoption of new technologies.
Conclusion
India Globalization Capital Inc. has positioned itself strategically in the healthcare and wellness sectors, with a focus on innovative products and technology-driven solutions. The company is not only enhancing its product offerings but is also embarking on various services to cater to a comprehensive range of customer needs in health and wellness. By focusing on these segments, IGC aims to be a leading player in the intersection of technology and healthcare, capitalizing on emerging trends and market demands.
Segments
1. Cannabis and Related Products:
- Medical Cannabis: IGC has been investing in the medical cannabis sector, focusing on developing formulations that can be used for treating various ailments. This includes research and development of cannabinoid-based products that cater to medical needs. The company aims to capitalize on the growing acceptance and legalization of cannabis across various regions.
2. Pharmaceuticals and Nutraceuticals:
- Nutraceutical Products: The company is involved in developing a range of nutraceuticals derived from natural sources, aimed at promoting health and wellness. These products often include dietary supplements and herbal formulations.
- Pharmaceutical Development: IGC is also exploring the pharmaceutical sector by developing drugs that address critical health issues, particularly those related to chronic diseases and conditions prevalent in the markets it targets.
3. Technology Solutions:
- Innovative Technologies: IGC is engaged in developing technology solutions that enhance operations in its core sectors. This could range from software development for healthcare management to digital platforms that facilitate patient interactions or telemedicine.
Products
1. Medicinal Products:
- Cannabidiol (CBD) Forms: The company offers various CBD products aimed at alleviating symptoms of chronic pain, anxiety, and other medical conditions. These products may come in capsules, oils, tinctures, and topical applications.
- Pharmaceutical Formulations: IGC is working on formulations that leverage pharmaceutical compounds combined with natural ingredients to treat illnesses more effectively.
2. Health Supplements:
- Vitamins and Minerals: The company markets a range of health supplements tailored for different demographics and health needs.
- Herbal Products: Formulations based on traditional medicinal practices are also part of the product line, focusing on holistic wellness.
3. Technology Products:
- Software Solutions: The development of software applications that support health care providers in managing patient care, enhancing communication, and streamlining service delivery is a key focus.
Services
1. Consultation Services:
- IGC provides consulting services in relation to product development, regulatory compliance, and market entry strategies in the healthcare sector.
2. Research and Development:
- The company offers R&D services, focusing on creating novel formulations, conducting clinical trials, and ensuring compliance with health regulations.
3. Distribution and Logistics:
- IGC manages logistics and distribution services to ensure that its products reach the market efficiently and effectively. This includes establishing supply chain networks that support the timely delivery of medical and wellness products.
4. Education and Training:
- IGC is likely involved in providing educational resources to healthcare providers, enabling them to understand and utilize its products effectively while also training personnel in the adoption of new technologies.
Conclusion
India Globalization Capital Inc. has positioned itself strategically in the healthcare and wellness sectors, with a focus on innovative products and technology-driven solutions. The company is not only enhancing its product offerings but is also embarking on various services to cater to a comprehensive range of customer needs in health and wellness. By focusing on these segments, IGC aims to be a leading player in the intersection of technology and healthcare, capitalizing on emerging trends and market demands.